Healthcare

PYC's Phase 2 Clinical Trial Progress: Successful Toxicology Tests Boost ASX Health Stocks

July 19, 2023 07:15 AM AEST| By Team Kalkine Media

PYC Therapeutics Limited (ASX: PYC), a biotechnology company focused on developing gene therapies for genetic diseases, has recently achieved a significant milestone in its Phase 2 clinical trial. The successful completion of toxicology tests for its...

Shareholders of EMVision Medical Devices (ASX: EMV) have Gained 11% in the Past Week

July 14, 2023 04:40 PM AEST| By Team Kalkine Media

Shareholders of EMVision Medical Devices (ASX: EMV) have experienced a notable gain of 11% in the past week. This positive performance reflects the upward momentum of the company's shares and highlights the potential opportunities within,ASX healthca...

ImpediMed (ASX:IPD): Can It Fulfill Its Growth Plans Successfully?

July 12, 2023 02:56 PM AEST| By Team Kalkine Media

ImpediMed (ASX:IPD) is a healthcare company listed on the ASX that specializes in the development and commercialization of medical devices for non-invasive fluid management. With its unique technology, ImpediMed aims to provide solutions for patients...

Record-Breaking Performance: Three ASX Healthcare Stocks Achieve Phenomenal Growth of 20% to 100% Today

July 04, 2023 04:47 PM AEST| By Team Kalkine Media

ASX healthcare stocks,that have delivered remarkable growth, ranging from 20% to 100% in a single day. These companies have demonstrated their potential to outperform the market and have caught the attention of investors seeking lucrative opportuniti...

From Medical Advances to Financial Gains: Riding the Wave of ASX Healthcare Stocks

June 30, 2023 09:23 PM AEST| By Team Kalkine Media

Investing in ASX healthcare stocks can be a lucrative opportunity for investors looking to capitalize on medical advances and the growing demand for healthcare services. The healthcare sector is experiencing rapid growth and innovation, driven by tec...

Nurturing Prosperity: How ASX Healthcare Stocks Can Fuel Your Investment Strategy and Financial Well-being

June 26, 2023 02:26 PM AEST| By Team Kalkine Media

Investing in ASX healthcare stocks provides an opportunity to capitalize on the growing demand for healthcare products and services. The healthcare sector is a crucial component of the economy, offering a wide range of companies involved in pharmaceu...

PolyNovo Limited (ASX: PNV) jumps over 16% on record sales in May 2023

June 07, 2023 11:31 AM AEST| By Priyabrata Prusty

The trigger behind today's movement in PNV shares is a sales update released by the company today morning. As per the release, the company recorded its first ever AU$ 7 million sales month in the month of May 2023.

Why did Next Science (ASX: NXS) surge above 28% on Friday?

May 26, 2023 06:36 PM AEST| By Neha Simpy

Next Science Limited (ASX: NXS) conducted its AGM, which was addressed by its Chair, along with its MD and CEO. NXS ended Friday’s trading session rocketing by 28.571% to AU$0.630. NXS’ MD & CEO mentioned that there was a 40% rise in product sales...

Mesoblast (ASX: MSB) narrows losses in 3Q FY23; shares increase 6%

May 26, 2023 11:53 AM AEST| By Neha Simpy

Mesoblast Limited (ASX: MSB) announced its operational and financial results for the quarter ended 31 March 2023. In 3Q FY23 results, MSB’s revenue from sales of TEMCELL® HS Inj. sold in Japan by its licensee for 3Q FY23 were US$1.8 million.

Amplia Therapeutics (ASX:ATX) Secures Grant Funding for Collaborative Research with CSIRO

May 22, 2023 05:47 PM AEST| By Team Kalkine Media

Amplia Therapeutics, a leading biotechnology company listed on the Australian Securities Exchange (ASX) under the ticker symbol ATX, has recently announced that it has secured grant funding for collaborative research with CSIRO.

Why did Rhythm Biosciences Ltd (ASX: RHY) soar over 100% on Wednesday?

May 17, 2023 07:22 PM AEST| By Neha Simpy

Rhythm Biosciences Limited (ASX: RHY) rose as much as 120% intraday and ended Wednesday, 17 May 2023, jumping by 95.714% to AU$0.685 after it updated that its product, ColoStat®, has secured UKCA Mark.

Healthy Returns: Investing in ASX Healthcare Stocks for Long-Term Growth

May 16, 2023 05:17 PM AEST| By Team Kalkine Media

Investing in the stock market is a great way to build long-term wealth. One sector that has consistently performed well in the ASX is the healthcare sector. With a growing and aging population, the demand for healthcare services

NEU, TLX: Two ASX200 healthcare stocks with over 200% one-year gains

May 12, 2023 03:46 PM AEST| By Neha Simpy

The S&P/ASX200 healthcare index is up 9.87% in one year, as of Friday. Two healthcare companies- Neuren Pharmaceuticals Limited (ASX: NEU) and Telix Pharmaceuticals Limited (ASX: TLX), which have surpassed the index by rising 297% and 217.7%.

NEU, CUV: Why these two ASX healthcare stocks declined on Tuesday

May 09, 2023 06:53 PM AEST| By Neha Simpy

The the sub-sector S&P/ASX200 Healthcare index closed the day, plummeting by 0.57%. Also, Neuren Pharmaceuticals Limited (ASX: NEU) and Clinuvel Pharmaceuticals Limited (ASX: CUV) closed Tuesday’s trading session, plunging by 0.794% and 1.560%.

Sonic (ASX: SHL) to acquire Medical Laboratories Duesseldorf for AU$298m; shares fall

April 26, 2023 11:32 AM AEST| By Neha Simpy

On 26 April 2023, Sonic Healthcare Limited (ASX: SHL) notified that it had inked binding deals to acquire one of the leading clinical laboratories in Duesseldorf-based Medical Laboratories Duesseldorf (MLD).

Why is this ASX 200 stock up over 230% in the last one year?

April 12, 2023 09:40 AM AEST| By Neha Simpy

The S&P/ASX 200 is a benchmark index for the Australian stock market. It has declined 3.01% in the last one year period, as of Tuesday, 11 April 2023. Compared to it, in the same period, Neuren Pharmaceuticals Limited (ASX: NEU) has gained 231.79%.

ImpediMed (ASX: IPD): This ASX biotech stock almost doubles in a day. Here's why

March 27, 2023 09:19 PM AEDT| By Neha Simpy

Highlights:,On Monday, ImpediMed Limited (ASX: IPD) announced an,updated NCCN Guidelines,®,to recommend frequent screening of lymphoedema with BIS.,The company has the only FDA-cleared BIS technology for the evaluation of lymphoedema.,In 2Q FY23, IPD...